• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

OLMESARTAN Drug Record

  • Summary
  • Interactions
  • Claims
  • OLMESARTAN chembl:CHEMBL1516

    Alternate Names:

    OLMESARTAN
    RNH-6270
    4-(1-HYDROXY-1-METHYLETHYL)-2-PROPYL-1-{[2'-(1H-TETRAZOL-5-YL)BIPHENYL-4-YL]METHYL}-1H-IMIDAZOLE-5-CARBOXYLIC ACID
    4-(HYDROXY-1-METHYLETHYL)-2-PROPYL-1-{[2'-(1H-TETRAZOL-5-YL)-1,1'-BIPHENYL-4-YL]METHYL}-1H-IMIDAZOLE-5-CARBOXYLIC ACID
    rxcui:321064
    chemidplus:144689-24-7
    drugbank:00275
    chembl:CHEMBL1516
    pubchem.compound:158781

    Drug Info:

    Drug Indications for treatment of glaucoma
    FDA Approval approved
    Drug Class Small Molecule
    Drug Indications antihypertensive agent
    Year of Approval 2002
    Drug Class antihypertensive agents
    (1 More Sources)

    Publications:

    Mire et al., 2005, A review of the structural and functional features of olmesartan medoxomil, an angiotensin receptor blocker., J. Cardiovasc. Pharmacol.
    Koike et al., 2001, In vitro and in vivo pharmacology of olmesartan medoxomil, an angiotensin II type AT1 receptor antagonist., J Hypertens Suppl
    Kreutz et al., 2006, Pharmacokinetics of olmesartan medoxomil plus hydrochlorothiazide combination in healthy subjects., Clin Drug Investig
    Ochiai et al., 2006, Functional and bioenergetic consequences of AT1 antagonist olmesartan medoxomil in hearts with postinfarction LV remodeling., J. Cardiovasc. Pharmacol.
    Chen et al., 2002, TTD: Therapeutic Target Database., Nucleic Acids Res.
    Warner et al., 2002, Olmesartan medoxomil., Drugs
    Suwannakul S et al., 2008, Pharmacokinetic interaction between pravastatin and olmesartan in relation to SLCO1B1 polymorphism., J Hum Genet
  • OLMESARTAN   AGTR1

    Interaction Score: 5.68

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:
    Direct Interaction yes
    Mechanism of Interaction Type-1 angiotensin II receptor antagonist
    Trial Name CS-8663, amlodipine + olmesartan,Azor, Sevikar

    PMIDs:
    16220064 11451212 17163232 16775509 11752352 12076183


    Sources:
    TdgClinicalTrial ChemblInteractions TEND

  • OLMESARTAN   SLCO1B1

    Interaction Score: 1.19

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    18641915


    Sources:
    PharmGKB

  • TEND: OLMESARTAN

    • Version: 01-August-2011

    Alternate Names:
    OLMESARTAN Primary Drug Name

    Drug Info:
    Drug Class antihypertensive agents
    Year of Approval 2002

    Publications:

  • TdgClinicalTrial: OLMESARTAN

    • Version: January-2014

    Alternate Names:

    Drug Info:
    Drug Indications antihypertensive agent
    Drug Class Small Molecule
    FDA Approval approved

    Publications:

  • PharmGKB: olmesartan

    • Version: 18-August-2020

    Alternate Names:

    Drug Info:

    Publications:
    Suwannakul S et al., 2008, Pharmacokinetic interaction between pravastatin and olmesartan in relation to SLCO1B1 polymorphism., J Hum Genet

  • ChemblInteractions: CHEMBL1516

    • Version: chembl_23

    Alternate Names:

    Drug Info:

    Publications:

  • ChemblDrugs: chembl:CHEMBL1516

    • Version: ChEMBL_27

    Alternate Names:

    Drug Info:

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21